Encora Therapeutics
Encora Therapeutics is a Boston-based company leveraging advances in wearable technology, signal processing, and patient sensing to develop affordable, personalized, non-invasive solutions for neurological movement disorders, particularly tremors. Their mission is to provide useful technology to benefit patients as quickly as possible.
Industries
Nr. of Employees
small (1-50)
Encora Therapeutics
Products
Investigational wrist-worn wearable for hand tremor relief
A wrist-worn, non-invasive investigational device using vibrotactile stimulation to reduce upper-limb tremor in adults with essential tremor or Parkinson's disease; evaluated in randomized sham-controlled studies.
Investigational wrist-worn wearable for hand tremor relief
A wrist-worn, non-invasive investigational device using vibrotactile stimulation to reduce upper-limb tremor in adults with essential tremor or Parkinson's disease; evaluated in randomized sham-controlled studies.
Services
Design and conduct of double-blind, randomized, sham-controlled, cross-over clinical studies to evaluate wearable device safety and efficacy in adults with hand tremors.
Online patient registry and research signup workflow to identify and contact individuals with hand tremors for potential study participation.
Design and conduct of double-blind, randomized, sham-controlled, cross-over clinical studies to evaluate wearable device safety and efficacy in adults with hand tremors.
Online patient registry and research signup workflow to identify and contact individuals with hand tremors for potential study participation.
Expertise Areas
- Wearable therapeutics for movement disorders
- Clinical trial management for medical devices
- Signal processing for physiological signals
- Neuromechatronics engineering
Key Technologies
- Vibrotactile stimulation
- Wearable sensor systems
- Wrist-worn therapeutic devices
- Signal processing algorithms for movement data
News & Updates
The 47-patient ULTRE study was a double-blind, randomized, sham-controlled, cross-over clinical trial comparing vibrotactile stimulation paradigms with an inactive sham control, adhering to rigorous scientific standards.
The FDA Breakthrough Device Program accelerates the development and review of innovative medical devices that demonstrate promise to substantially improve care for patients with life-threatening or debilitating conditions.
The 47-patient ULTRE study was a double-blind, randomized, sham-controlled, cross-over clinical trial comparing vibrotactile stimulation paradigms with an inactive sham control, adhering to rigorous scientific standards.
The FDA Breakthrough Device Program accelerates the development and review of innovative medical devices that demonstrate promise to substantially improve care for patients with life-threatening or debilitating conditions.